AML competition

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
jayfish101
Posts: 128
Joined: Tue Feb 23, 2016 5:48 pm

AML competition

Post by jayfish101 » Thu Dec 07, 2023 12:55 am

Syros Pharmaceuticals (NASDAQ: SYRS) announced initial data from its Phase 2 SELECT-AML-1 trial evaluating tamibarotene with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The preliminary data resulted in a 100% CR/CRi rate in patients treated with tamibarotene, venetoclax, and azacitidine compared to 70% in patients randomized to treatment with venetoclax and azacitidine alone. Shares closed up 43% at $4.02.
Top
biopearl123
Posts: 1670
Joined: Fri Jul 20, 2018 5:13 pm

Re: AML competition

Post by biopearl123 » Thu Dec 07, 2023 3:10 am

Interesting, thanks for posting Jay.
Top
jingledsassy
Posts: 54
Joined: Wed Jul 13, 2016 4:15 pm

Re: AML competition

Post by jingledsassy » Thu Dec 07, 2023 12:59 pm

Hmmm wonder why this wasn't accepted for the ASH conf??
Top
Post Reply

Return to “ImetelChat”